Adimmune Corporation (4142) announced today that its first overseas manufacturing site will be located in JIIPE Industrial Estate in Indonesia. The new site in Indonesia is designed to be a multiple technologies biologics manufacturing platform and serve as Adimmune’s beachhead to the Southeast Asia market. Through building overseas facilities, Adimmune is realizing its global expansion and enhancing the connection with the international markets. Compliant with Taiwan’s New Southbound Policy, Adimmune will become Taiwan’s forerunner among vaccine manufacturers capable of attracting international funding and partnerships.
The signing of the MOU and the proposed project plan results from a continuous dialogue regarding bio-medical collaboration between Adimmune and Indonesia over the past year. While the Indonesian government has just designated JIIPE as a special economic zone (SEZ), Adimmune is signing the MOU with BKMS, the developer of JIIPE, and plans to build a biologics manufacturing center in the SEZ, which is the first overseas manufacturing site of Adimmune, and will become a center for a variety of biologics manufacturing for future CDMO projects. This is a substantial milestone for Adimmune to penetrate the global markets, including Southeast Asia.
Indonesia is the fourth most populous country worldwide and has the largest Muslim population in the world. Adimmune, in collaboration with Indonesia, is actively expanding into the Southeast Asia market. Having acquired Halal certification for many of its vaccines, Adimmune has advantages for accessing the Muslim countries, and created a pathway to the ASEAN countries in alignment with Taiwan’s New Southbound Policy. Via collaboration with Indonesia to produce biologics, Adimmune can further connect with international markets, such as Europe, the United States, and Japan.
Adimmune stressed that with the objective of operating as a sustainable business in mind, its products and CDMO services will have to reach out to the global market. In order to attract international funding and new technologies as well as to position itself in line with Taiwan’s New Southbound Policy, Adimmune will explore opportunities overseas and build new manufacturing sites on the basis of its core technologies to accelerate the company’s globalization and promote cross-border collaborations of technologies and solidify a biologics supply chain for the well-being of the public.